168P Liver metastases (mets) and treatment effect of cemiplimab-based therapy: An analysis from three phase III trials (EMPOWER-Lung 1, EMPOWER-Lung 3 part 2, and EMPOWER-Cervical 1)
Immuno-Oncology and Technology(2022)
摘要
Emerging data suggest that liver mets are immune privileged and can induce systemic loss of tumour specific CD8+ T cells, leading to reduced anti-tumour immunity. Liver mets were shown to negatively predict the success of immunotherapy (as opposed to chemotherapy [chemo] or targeted therapy) in several cancer types. However, limited prospective data exist on the effect of immunotherapy in patients (pts) with liver mets.
更多查看译文
关键词
phase iii trials,liver,cemiplimab-based,empower-lung,empower-lung,empower-cervical
AI 理解论文
溯源树
样例
![](https://originalfileserver.aminer.cn/sys/aminer/pubs/mrt_preview.jpeg)
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要